Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Narra J
R, Subramaniam
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America Rosiello, Dott F.; Anwar, Samsul; Yufika, Amanda; Adam, Rashed Y.; Ismaeil, Mohajer IH.; Ismail, Asma Y.; Dahman, Nesrine BH.; Hafsi, Montacer; Ferjani, Manel; Sami, Farah S.; Monib, Fatma A; R, Subramaniam; Anandu, Sunil; Haque, Md Ariful; Ferreto, Lirane ED.; Aburto, José TO.; Rojas, Jorge ET.; Enitan, Seyi S.; Yomi, Akele R.; Ezigbo, Eyiuche D.; Babadi, Elham; Kakemam, Edris; Malik, Najma I.; Ullah, Irfan; Sallam, Malik
Narra J Vol. 1 No. 3 (2021): December 2021
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v1i3.55

Abstract

Vaccine hesitancy, defined as the reluctance or rejection in receiving a vaccine despite its availability, represents a major challenge to global health efforts aiming to control the ongoing COVID-19 pandemic. Understanding the possible factors correlated with COVID-19 vaccine hesitancy using a refined well-informed approach can be helpful to address the phenomenon. The current study aimed to evaluate COVID-19 vaccine acceptance rates using four hypothetical scenarios of varying levels of vaccine efficacy and safety profiles in ten Asian, African and South American countries. These scenarios included: 95% efficacy and 20% side effects (Vaccine A), 75% efficacy and 5% side effects (Vaccine B); 75% efficacy and 20% side effects (Vaccine C) and 50% efficacy and 5% side effects (Vaccine D). This study used a self-administered online survey that was distributed during February–May 2021. The total number of study respondents was 1337 with countries of residence as follows: India (21.1%), Pakistan (12.9%), Sudan (11.2%), Nigeria (9.3%), Iran (8.2%), Bangladesh and Brazil (7.9%), Chile (7.7%), Tunisia (7.6%), and Egypt (6.2%). The overall acceptance rates for COVID-19 vaccination were variable based on varying degrees of safety and efficacy as follows: 55.6% for Vaccine C, 58.3% for Vaccine D, 74.0% for Vaccine A and 80.1% for Vaccine B. The highest levels of COVID-19 vaccine acceptance were observed in Brazil followed by Chile across the four different safety and efficacy scenarios. The lowest COVID-19 vaccine acceptance rates were reported in Egypt and Tunisia for the low safety scenarios (20% side effects), and the low efficacy scenario (50% efficacy). The study revealed the potential effect of vaccine safety and efficacy on the intention to get COVID-19 vaccination. At the same efficacy level, higher possibility of side effects caused a large drop in COVID-19 vaccine acceptance rate. This indicates the importance of accurate communication regarding vaccine safety and efficacy on attitude towards the vaccine and intentions to get vaccinated. Regional differences in COVID-19 vaccine acceptance were observed with the Middle East/North African countries showing the lowest rates and the South American countries displaying the highest vaccine acceptance rates.
Co-Authors Aburto, José TO. Adam, Rashed Y. Anandu, Sunil Babadi, Elham Dahman, Nesrine BH. Enitan, Seyi S. Ezigbo, Eyiuche D. Ferjani, Manel Ferreto, Lirane ED. Hafsi, Montacer Haque, Md Ariful Ismaeil, Mohajer IH. Ismail, Asma Y. Kakemam, Edris Malik, Najma I. Monib, Fatma A Rojas, Jorge ET. Rosiello, Dott F. Sallam, Malik Sami, Farah S. Samsul Anwar Ullah, Irfan Yomi, Akele R. Yufika, Amanda